47045-VEN-C-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria Venezuela (Bolivarian Republic), TB/HIV, United Nations Development Programme Goals: Reducir los nuevos casos de VIH, con enfoque en las poblaciones clave/Reducing new HIV cases, focusing on key populations; Ampliar la cobertura y calidad del tratamiento antirretroviral, con énfasis en las poblaciones clave para el VIH/ Expand coverage and quality of antiretroviral treatment, with emphasis on key populations for HIV; Reducir de la carga de tuberculosis en todas sus formas entre las poblaciones vulnerables/ Reducing the burden of tuberculosis in all its forms among vulnerable populations; Asegurar la prevención, el abordaje y el tratamiento de la coinfección TB/VIH/ Ensure prevention, management and treatment of TB/HIV coinfection. Objectives: Facilitar el acceso de las poblaciones clave a los servicios de prevención y diagnóstico de VIH con participación comunitaria / Facilitate access of key populations to HIV prevention and diagnostic services with community participation; Asegurar el tratamiento antirretroviral continuado para todas las personas que lo necesiten, con énfasis en las poblaciones clave y en participación con la comunidad / Ensure continued antiretroviral treatment for all people in need, with emphasis on key populations and in partnership with the community; Reducir el estigma y la discriminación asociados al VIH y a las poblaciones clave, especialmente en los servicios de salud / Reduce stigma and discrimination associated with HIV and key populations, especially in health services; Fortalecer la vinculación de las poblaciones clave a servicios de atención de calidad para el VIH/Strengthen linkage of key populations to quality HIV care services; Fortalecer la oferta de servicios de prevención, diagnóstico y tratamiento de la tuberculosis en todas sus formas para las poblaciones vulnerables / Strengthen linkage of key populations to quality HIV care services; Asegurar el diagnóstico y la atención de calidad para las personas con TB-RR/MDR / Ensuring quality diagnosis and care for people with MDR/RR-TB; Implementar las actividades colaborativas entre los programas de VIH y de tuberculosis / Implement collaborative activities between HIV and tuberculosis programs. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Cecilia Vitale Fund Portfolio Manager +41 58 791 1700 cecilia.vitale@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Venezuela (Bolivarian Republic) HIV Multicomponent, RSSH Tuberculosis Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing for KP programs HIV -> Differentiated HIV Testing Services -> Facility-based testing outside of key population (KP) and adolescent girls and young women (AGYW) programs HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Community empowerment for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Condom and lubricant programming for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> HIV prevention communication, information and demand creation for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for MSM HIV -> Prevention package for sex workers, their clients and other sexual partners -> Community empowerment for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Condom and lubricant programming for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> HIV prevention communication, information and demand creation for sex workers HIV -> Prevention package for transgender people and their sexual partners -> Community empowerment for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Condom and lubricant programming for transgender people HIV -> Prevention package for transgender people and their sexual partners -> HIV prevention communication, information and demand creation for transgender people HIV -> Prevention package for transgender people and their sexual partners -> Pre-exposure prophylaxis (PrEP) programming for transgender people HIV -> Reducing human rights-related barriers to HIV/TB services -> Improving laws, regulations and policies relating to HIV and HIV/TB HIV -> Reducing human rights-related barriers to HIV/TB services -> Reducing HIV-related gender discrimination, harmful gender norms and violence against women and girls in all their diversity HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Multicomponent -> Program management -> Coordination and management of national disease control programs Multicomponent -> Program management -> Grant management RSSH -> RSSH: Community systems strengthening -> Community-led monitoring RSSH -> RSSH: Monitoring and evaluation systems -> Analyses, evaluations, reviews and data use Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Children and adolescents Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Others Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - People in prisons/jails/detention centers Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB diagnosis, treatment and care -> TB treatment, care and support Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis Tuberculosis -> TB/HIV -> TB/HIV - Treatment and care 4448735.55 4535333.06 10672862.46 9843940.50 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5523476.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1477685.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2842779.50 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5498239.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4582989.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3687751.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -915250.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3687751.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1542250.50 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 940458.50 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -601792.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2369977.00 Global Fund commitment to VEN-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2369977.00 Global Fund disbursement to VEN-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4898171.71 Expenditure reported by United Nations Development Programme for VEN-C-UNDPP01, Jan 2024 to Dec 2024. United Nations Development Programme 4097123.42 Expenditure reported by United Nations Development Programme for VEN-C-UNDPP01, Jan 2025 to Dec 2025. United Nations Development Programme An overview of a grant over its lifetime. General terms and conditions which apply to Global Fund grants. Funding Request of funding request FR1409-VEN-C. Funding Request of funding request FR1409-VEN-C. 1 - Personal Data. (1) Principles. Program Activities are expected to respect the following principles and rights (“Data Protection Principles”): (a) Information that could be used to identify a natural person (“Personal Data”) will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes;  (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and (b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing. (2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles: (a) to the extent that doing so does not violate or conflict with any law and/or policy applicable to it; and (b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons. (3) The Global Fund may collect or seek to collect data, and it is possible that such data may contain Personal Data. Prior to collection and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any law or regulation applicable to the Principal Recipient. 2 - To the extent consistent with and without prejudice to the Framework Agreement and, in particular, Article 2 of the UNDP-Global Fund Grant Regulations, the Principal Recipient shall be guided by the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time, available at the Global Fund’s Internet site) in the budgeting of the Grant. 3 - Under Article 3 of the UNDP-Global Fund Grant Regulations, the “Grant” consists of “funds as stated in the relevant Grant Confirmation together with any funds previously granted by the Global Fund to the Principal Recipient for the Program”. In this regard, please note that where the Global Fund has approved the use under the current Grant Confirmation of grant funds disbursed to the Principal Recipient under a previous Grant Agreement for the Program (“Previously Disbursed Grant Funds”), the Global Fund may reduce the amount of Grant Funds that remains uncommitted set forth in Section 3.6 of the Grant Confirmation by the amount of any Previously Disbursed Grant Funds, upon written notification to the Principal Recipient. 4 - UNDP shall reasonably ensure that Grant Funds are not used by UNDP in contravention of any sanctions applicable to it prohibiting or materially restricting the disbursement and/or use of Grant Funds or, implementation of Program Activities and notify the Global Fund of any possible or actual contravention of such sanctions. UNDP shall reasonably ensure, including through the inclusion and enforcement of contractual obligations, that any Sub-recipient and supplier shall: (a) reasonably ensure that no Grant Funds are used or disbursed in contravention of any laws and regulations applicable to it, including sanctions; (b) provide prompt notice to UNDP of any material due diligence findings inconsistent with and/or in contravention of such laws and regulations; and (c) ensure that the same undertaking is included in any downstream contracts with Sub-sub-recipients and/or suppliers. In the event of a contravention of this clause, UNDP and the Global Fund shall promptly consult each other with a view to jointly determining remedial measures in accordance with their respective applicable legal framework. This provision is without prejudice to the Global Fund’s existing remedies under the Framework Agreement or to the exceptions contained in any applicable sanctions. 5 - No later than 30 June 2024, the Principal Recipient shall submit to the Global Fund and obtain the Global Fund’s prior written approval of: a grant-specific monitoring & evaluation plan for HIV and TB. 6 - Unless otherwise notified by the Global Fund in writing, prior to the use of Grant Funds to finance the procurement of second-line anti-tuberculosis drugs and for each disbursement request that includes funds for the procurement of multi-drug resistant tuberculosis medicines, the Principal Recipient shall submit to the Global Fund and obtain the Global Fund’s written approval of a written confirmation of the price estimate and quantities of the second-line anti-tuberculosis drugs that will be procured by the Principal Recipient from the Global Drug Facility’s procurement agent. 7 - The Principal Recipient shall take all appropriate and necessary actions to ensure that it and any Sub-recipient complies with the “Asset Guidelines for Global Fund Grant Transitions” dated 2 June 2023 (as amended from time to time), the provisions of which are incorporated by reference into the Grant Agreement. Module: Drug-resistant (DR)-TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 84. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 0; Denominator: 84; Percentage: 0%. Numerator: 0; Denominator: 84; Percentage: 0%. Numerator: 75. Numerator: 150. Numerator: 121. Numerator: 75. Numerator: 63. Numerator: 118. Numerator: 3. Numerator: 43. Numerator: 78. Numerator: 113. Numerator: 8. Numerator: 0. Numerator: 200. Numerator: 84. Numerator: 100. Numerator: 100. Numerator: 51. Numerator: 50. Numerator: 1000. Numerator: 16. Numerator: 35. Numerator: 51. Numerator: 0. Numerator: 0. Numerator: 125. Numerator: 125. Module: Drug-resistant (DR)-TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 82; Denominator: 84; Percentage: 97.62%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 2; Denominator: 84; Percentage: 2.38%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 32; Denominator: 84; Percentage: 38.1%. Numerator: 68; Denominator: 84; Percentage: 80.95%. Numerator: 68; Denominator: 84; Percentage: 80.95%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 52; Denominator: 84; Percentage: 61.9%. Numerator: 16; Denominator: 84; Percentage: 19.05%. Numerator: 16; Denominator: 84; Percentage: 19.05%. Numerator: 84; Denominator: 84; Percentage: 100%. Numerator: 75; Denominator: 75; Percentage: 100%. Numerator: 150; Denominator: 150; Percentage: 100%. Numerator: 119; Denominator: 121; Percentage: 98.35%. Numerator: 75; Denominator: 75; Percentage: 100%. Numerator: 62; Denominator: 63; Percentage: 98.41%. Numerator: 116; Denominator: 118; Percentage: 98.31%. Numerator: 3; Denominator: 3; Percentage: 100%. Numerator: 42; Denominator: 43; Percentage: 97.67%. Numerator: 0. Numerator: 77; Denominator: 78; Percentage: 98.72%. Numerator: 119. Numerator: 200; Denominator: 200; Percentage: 100%. Numerator: 84; Denominator: 84; Percentage: 100%. Numerator: 100; Denominator: 100; Percentage: 100%. Numerator: 100; Denominator: 100; Percentage: 100%. Numerator: 51; Denominator: 51; Percentage: 100%. Numerator: 50; Denominator: 50; Percentage: 100%. Numerator: 1; Denominator: 1; Percentage: 100%. Numerator: 16; Denominator: 16; Percentage: 100%. Numerator: 0. Numerator: 35; Denominator: 35; Percentage: 100%. Numerator: 51. Numerator: 125; Denominator: 125; Percentage: 100%. Numerator: 125; Denominator: 125; Percentage: 100%. Module: Drug-resistant (DR)-TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 23; Denominator: 34; Percentage: 67.65%. Numerator: 19; Denominator: 19; Percentage: 100%. Numerator: 19; Denominator: 19; Percentage: 100%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 7; Denominator: 11; Percentage: 63.64%. Numerator: 7; Denominator: 11; Percentage: 63.64%. Numerator: 13; Denominator: 19; Percentage: 68.42%. Numerator: 13; Denominator: 19; Percentage: 68.42%. Numerator: 12; Denominator: 17; Percentage: 70.59%. Numerator: 12; Denominator: 17; Percentage: 70.59%. Numerator: 20; Denominator: 27; Percentage: 74.07%. Numerator: 20; Denominator: 27; Percentage: 74.07%. Numerator: 0; Denominator: 1; Percentage: 0%. Numerator: 0; Denominator: 1; Percentage: 0%. Numerator: 0. Numerator: 0. Numerator: 20; Denominator: 28; Percentage: 71.43%. Numerator: 20; Denominator: 28; Percentage: 71.43%. Numerator: 15; Denominator: 19; Percentage: 78.95%. Numerator: 15; Denominator: 19; Percentage: 78.95%. Numerator: 0; Denominator: 19; Percentage: 0%. Numerator: 0; Denominator: 19; Percentage: 0%. Percentage: 70%. Numerator: 67; Denominator: 84; Percentage: 79.76%. Percentage: 70%. Numerator: 67; Denominator: 84; Percentage: 79.76%. Numerator: 66. Numerator: 1. Numerator: 25; Denominator: 30; Percentage: 83.33%. Numerator: 9. Numerator: 41; Denominator: 54; Percentage: 75.93%. Numerator: 63. Numerator: 3. Numerator: 0. Numerator: 67; Denominator: 84; Percentage: 79.76%. Numerator: 56. Numerator: 0. Percentage: 70%. Numerator: 117; Denominator: 153; Percentage: 76.47%. Percentage: 70%. Numerator: 117; Denominator: 153; Percentage: 76.47%. Numerator: 60; Denominator: 77; Percentage: 77.92%. Numerator: 0; Denominator: 0. Numerator: 18; Denominator: 25; Percentage: 72%. Numerator: 0. Numerator: 42; Denominator: 52; Percentage: 80.77%. Numerator: 56; Denominator: 72; Percentage: 77.78%. Numerator: 4; Denominator: 5; Percentage: 80%. Numerator: 0; Denominator: 0. Numerator: 60; Denominator: 77; Percentage: 77.92%. Numerator: 60. Numerator: 0; Denominator: 0. Percentage: 70%. Module: Key and vulnerable populations (KVP) - TB/DR-TB. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Module: TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 9865. Numerator: 9358; Denominator: 9865; Percentage: 94.86%. Numerator: 9358; Denominator: 9865; Percentage: 94.86%. Numerator: 507; Denominator: 9865; Percentage: 5.14%. Numerator: 507; Denominator: 9865; Percentage: 5.14%. Numerator: 7294; Denominator: 9865; Percentage: 73.94%. Numerator: 7294; Denominator: 9865; Percentage: 73.94%. Numerator: 3761; Denominator: 9865; Percentage: 38.12%. Numerator: 3761; Denominator: 9865; Percentage: 38.12%. Numerator: 6104; Denominator: 9865; Percentage: 61.88%. Numerator: 6104; Denominator: 9865; Percentage: 61.88%. Numerator: 4450; Denominator: 9865; Percentage: 45.11%. Numerator: 4450; Denominator: 9865; Percentage: 45.11%. Numerator: 426; Denominator: 9865; Percentage: 4.32%. Numerator: 426; Denominator: 9865; Percentage: 4.32%. Numerator: 4989; Denominator: 9865; Percentage: 50.57%. Numerator: 4989; Denominator: 9865; Percentage: 50.57%. Numerator: 11128. Numerator: 10641. Numerator: 5564. Numerator: 5564. Numerator: 5325. Numerator: 9989. Numerator: 652. Numerator: 8143. Numerator: 3890. Numerator: 6751. Numerator: 6688. Numerator: 578. Numerator: 3375. Numerator: 5925. Numerator: 11850. Numerator: 10805. Numerator: 5925. Numerator: 5873. Numerator: 5493. Numerator: 380. Numerator: 4636. Numerator: 2126. Numerator: 3747. Numerator: 3839. Numerator: 310. Numerator: 1714. Numerator: 6246. Numerator: 6246. Module: TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 424; Denominator: 9090; Percentage: 4.66%. Numerator: 424; Denominator: 9090; Percentage: 4.66%. Numerator: 1120; Denominator: 9865; Percentage: 11.35%. Numerator: 683; Denominator: 5689; Percentage: 12.01%. Numerator: 2048; Denominator: 11378; Percentage: 18%. Numerator: 6544; Denominator: 10641; Percentage: 61.5%. Numerator: 1365; Denominator: 5689; Percentage: 23.99%. Numerator: 4176; Denominator: 5325; Percentage: 78.42%. Numerator: 5883. Numerator: 5082; Denominator: 12100; Percentage: 42%. Numerator: 6238; Denominator: 10805; Percentage: 57.73%. Numerator: 2178; Denominator: 6050; Percentage: 36%. Numerator: 2904; Denominator: 6050; Percentage: 48%. Numerator: 3460; Denominator: 5873; Percentage: 58.91%. Numerator: 3137. Numerator: 3823; Denominator: 6371; Percentage: 60.01%. Numerator: 4587; Denominator: 6371; Percentage: 72%. Module: TB diagnosis, treatment and care. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 7681; Denominator: 9090; Percentage: 84.5%. Numerator: 7404; Denominator: 7681; Percentage: 96.39%. Numerator: 7404; Denominator: 7681; Percentage: 96.39%. Numerator: 277; Denominator: 7681; Percentage: 3.61%. Numerator: 277; Denominator: 7681; Percentage: 3.61%. Numerator: 2696; Denominator: 7681; Percentage: 35.1%. Numerator: 2696; Denominator: 7681; Percentage: 35.1%. Numerator: 4985; Denominator: 7681; Percentage: 64.9%. Numerator: 4985; Denominator: 7681; Percentage: 64.9%. Numerator: 3528; Denominator: 7681; Percentage: 45.93%. Numerator: 3528; Denominator: 7681; Percentage: 45.93%. Numerator: 265; Denominator: 7681; Percentage: 3.45%. Numerator: 265; Denominator: 7681; Percentage: 3.45%. Numerator: 3888; Denominator: 7681; Percentage: 50.62%. Numerator: 3888; Denominator: 7681; Percentage: 50.62%. Numerator: 8551; Denominator: 10060; Percentage: 85%. Numerator: 4360; Denominator: 4939; Percentage: 88.28%. Numerator: 4275.5; Denominator: 5030; Percentage: 85%. Numerator: 4275.5; Denominator: 5030; Percentage: 85%. Numerator: -126; Denominator: -287; Percentage: 43.9%. Numerator: 4109. Numerator: 256. Numerator: 1554. Numerator: 2791. Numerator: 2166. Numerator: 168. Numerator: 2026. Numerator: 9681.4; Denominator: 11128; Percentage: 87%. Numerator: 9292; Denominator: 10813; Percentage: 85.93%. Numerator: 4840.68; Denominator: 5564; Percentage: 87%. Numerator: 4840.68; Denominator: 5564; Percentage: 87%. Numerator: 2731; Denominator: 3047; Percentage: 89.63%. Numerator: 4343; Denominator: 5009; Percentage: 86.7%. Numerator: 284; Denominator: 327; Percentage: 86.85%. Numerator: 1778; Denominator: 2011; Percentage: 88.41%. Numerator: 2849; Denominator: 3325; Percentage: 85.68%. Numerator: 3016; Denominator: 3367; Percentage: 89.58%. Numerator: 246; Denominator: 310; Percentage: 79.35%. Numerator: 1365; Denominator: 1659; Percentage: 82.28%. Numerator: 5332.5; Denominator: 5925; Percentage: 90%. Numerator: 5332.5; Denominator: 5925; Percentage: 90%. Module: TB/HIV. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 410; Denominator: 426. Numerator: 410; Denominator: 426. Numerator: 12; Denominator: 426. Numerator: 12; Denominator: 426. Numerator: 4; Denominator: 426. Numerator: 4; Denominator: 426. Numerator: 121; Denominator: 426. Numerator: 121; Denominator: 426. Numerator: 305; Denominator: 426. Numerator: 305; Denominator: 426. Numerator: 426; Denominator: 426. Numerator: 422; Denominator: 578. Numerator: 280; Denominator: 333. Numerator: 395; Denominator: 552. Numerator: 20; Denominator: 17. Numerator: 7; Denominator: 9. Numerator: 144; Denominator: 156. Numerator: 418; Denominator: 422. Numerator: 518; Denominator: 548. Numerator: 283; Denominator: 304. Numerator: 486; Denominator: 516. Numerator: 18; Denominator: 18. Numerator: 14; Denominator: 14. Numerator: 120; Denominator: 127. Numerator: 398; Denominator: 421. Module: TB/HIV. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - special. Numerator: 123; Denominator: 60765; Percentage: 0.2%. Numerator: 121; Denominator: 123; Percentage: 98.37%. Numerator: 121; Denominator: 123; Percentage: 98.37%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 2; Denominator: 123; Percentage: 1.63%. Numerator: 2; Denominator: 123; Percentage: 1.63%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 22; Denominator: 123; Percentage: 17.89%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 101; Denominator: 123; Percentage: 82.11%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 0; Denominator: 123; Percentage: 0%. Numerator: 900; Denominator: 72533; Percentage: 1.2%. Numerator: 646; Denominator: 57484; Percentage: 1.12%. Numerator: 450; Denominator: 69270.5; Percentage: 0.65%. Numerator: 450; Denominator: 72533; Percentage: 0.62%. Numerator: 320; Denominator: 57484; Percentage: 0.56%. Numerator: 633. Numerator: 0. Numerator: 460. Numerator: 4. Numerator: 9. Numerator: 182. Numerator: 4. Numerator: 172. Numerator: 474. Numerator: 0. Numerator: 600; Denominator: 73627.5; Percentage: 0.81%. Numerator: 1200; Denominator: 74722; Percentage: 1.6%. Numerator: 685; Denominator: 66815; Percentage: 1.03%. Numerator: 600; Denominator: 74722; Percentage: 0.8%. Numerator: 379; Denominator: 66815; Percentage: 0.57%. Numerator: 369. Numerator: 0. Numerator: 365. Numerator: 4. Numerator: 4. Numerator: 9. Numerator: 6. Numerator: 80. Numerator: 299. Numerator: 1. Numerator: 1050; Denominator: 75817.5; Percentage: 1.38%. Numerator: 1050; Denominator: 76913; Percentage: 1.37%. Module: Treatment, care and support. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 15264; Denominator: 59749. Numerator: 15264; Denominator: 59749. Numerator: 44485; Denominator: 59749. Numerator: 44485; Denominator: 59749. Numerator: 57484; Denominator: 110000. Numerator: 68070.5; Denominator: 100301. Numerator: 71333; Denominator: 100301. Numerator: 56697; Denominator: 100301. Numerator: 71333; Denominator: 100301. Numerator: 56697; Denominator: 100301. Numerator: 14944; Denominator: 28205. Numerator: 41753; Denominator: 71675. Numerator: 64271; Denominator: 110000. Numerator: 66109; Denominator: 110000. Numerator: 72427.5; Denominator: 107133. Numerator: 64271; Denominator: 110000. Numerator: 66109; Denominator: 110000. Numerator: 16763; Denominator: 65942. Numerator: 49179; Denominator: 65942. Numerator: 65367; Denominator: 113000. Numerator: 66462; Denominator: 113000. Module: Treatment, care and support. Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 452; Denominator: 1016. Numerator: 452; Denominator: 1016. Numerator: 564; Denominator: 1016. Numerator: 564; Denominator: 1016. Numerator: 787; Denominator: 2900. Numerator: 1200; Denominator: 3416. Numerator: 1200; Denominator: 3416. Numerator: 787; Denominator: 3416. Numerator: 1200; Denominator: 3416. Numerator: 787; Denominator: 3416. Numerator: 368; Denominator: 1832. Numerator: 419; Denominator: 1932. Numerator: 1200; Denominator: 3438. Numerator: 1000; Denominator: 2900. Numerator: 873; Denominator: 2900. Numerator: 1000; Denominator: 2900. Numerator: 873; Denominator: 2900. Numerator: 417; Denominator: 873. Numerator: 456; Denominator: 873. Numerator: 1000; Denominator: 2750. Numerator: 1000; Denominator: 2750.